Article 1 to 1 out of 1 concerning Kadmus Pharmaceuticals
Organon announces acquisition of Kadmus Pharmaceuticals' FAAH inhibitor technology(28 Jun 2007) N.V. Organon, the human healthcare business unit of Akzo Nobel, announced an asset purchase of the Fatty Acid Amide Hydrolase (FAAH) technology from Kadmus Pharmaceuticals, Inc. in Irvine CA (USA).Under the asset purchase agreement, Organon has ...
Top
